nach oben

Neurological Sciences

Erschienen in:

11.03.2020 | Review Article

Levodopa/carbidopa/entacapone for the treatment of early Parkinson’s disease: a meta-analysis

verfasst von: Xiaoli Liao, Nianyue Wu, Dongfeng Liu, Bowei Shuai, Shilei Li, Ke Li

Erschienen in: Neurological Sciences | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Treatment of Parkinson’s disease with levodopa/carbidopa/entacapone (LCE) has been studied for a long time. However, the efficacy and safety of LCE in the treatment of early Parkinson’s disease (PD) still need to be assessed. Our objective was to do a meta-analysis of relevant randomized controlled trials (RCTs) to evaluate the efficacy and safety of LCE for early PD. PubMed, Embase, the Cochrane Library, and the Web of Science were searched for RCTs with “levodopa/carbidopa/entacapone” and “Parkinson’s disease” as keywords. The search period was from inception to October 2018. The quality of included studies was strictly evaluated. We evaluated the quality of included studies strictly and six studies met all inclusion criteria. The results showed that LCE could improve activities of daily living and motor function in PD patients. However, LCE therapy was associated with higher risks of total AEs and single AEs compared with traditional therapy.

Hirsch EC, Jenner P, Przedborski S (2013) Pathogenesis of Parkinson’s disease. Mov Disord 28(1):24–30. https://doi.org/10.1002/mds.25032 CrossRefPubMed

Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386(9996):896–912. https://doi.org/10.1016/s0140-6736(14)61393-3 CrossRefPubMed

Chen Y, Shen J, Ke K, Gu X (2020) Clinical potential and current progress of mesenchymal stem cells for Parkinson’s disease: a systematic review. Neurol Sci 1:11. https://doi.org/10.1007/s10072-020-04240-9 CrossRef

Gaenslen A, Berg D (2010) Early diagnosis of Parkinson’s disease. Int Rev Neurobiol 90:81–92. https://doi.org/10.1016/s0074-7742(10)90006-8 CrossRefPubMed

Ossig C, Reichmann H (2015) Treatment strategies in early and advanced Parkinson disease. Neurol Clin 33(1):19–37. https://doi.org/10.1016/j.ncl.2014.09.009 CrossRefPubMed

Brooks DJ (2008) Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat 4(1):39–47CrossRefPubMedPubMedCentral

Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of Parkinsonism—chronic treatment with L-dopa. N Engl J Med 280:337–345CrossRefPubMed

Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol 15(12):1257–1272. https://doi.org/10.1016/s1474-4422(16)30230-7 CrossRefPubMed

Gordin A, Kaakkola S, Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone—a review. J Neural Transm (Vienna) 111(10–11):1343–1363. https://doi.org/10.1007/s00702-004-0190-3 CrossRef

10.

Fung VSC, Herawati L, Wan Y, Boyle R, Hughes A, Lueck C et al (2009) Quality of life in early Parkinson’s disease treated with levodopa/carbidopa/entacapone. Mov Disord 24(1):25–31. https://doi.org/10.1002/mds.21878 CrossRefPubMed

11.

Poulopoulos M, Waters C (2010) Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease. Core Evid 5:1–10PubMedPubMedCentral

12.

Tveiten OV, Skeie GO, Haugarvoll K, Muller B, Larsen JP, Tysnes OB (2013) Treatment in early Parkinson’s disease: the Norwegian ParkWest study. Acta Neurol Scand 128(2):107–113. https://doi.org/10.1111/ane.12055 CrossRefPubMed

13.

Espay AJ, Pagan FL et al (2017) Optimizing extended-release carbidopa/levodopa in Parkinson disease: consensus on conversion from standard therapy. Neurol Clin Pract 7:86–93CrossRefPubMedPubMedCentral

14.

Abbruzzese G (2008) Optimising levodopa therapy. Neurol Sci 29:377–379. https://doi.org/10.1007/s10072-008-1051-x CrossRef

15.

Zambito Marsala S, Vitaliani R, Volpe D, Capozzoli F, Baroni L, Belgrado E, Borsato C, Gioulis M, Marchini C, Antonini A (2013) Rapid onset of efficacy of rasagiline in early Parkinson’s disease. Neurol Sci 34:2007–2013. https://doi.org/10.1007/s10072-013-1437-2 CrossRefPubMed

16.

Getz SJ, Levin B (2017) Cognitive and neuropsychiatric features of early Parkinson’s disease. Arch Clin Neuropsychol 32(7):769–785. https://doi.org/10.1093/arclin/acx091 CrossRefPubMed

17.

Lew MF, Somogyi M, McCague K, Welsh M (2011) Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson’s disease with end-of-dose wearing off. Int J Neurosci 121(11):605–613. https://doi.org/10.3109/00207454.2011.598982 CrossRefPubMed

18.

Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A, Grp F-SS (2009) Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s disease. Mov Disord 24(4):541–550. https://doi.org/10.1002/mds.22343 CrossRefPubMed

19.

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18–27. https://doi.org/10.1002/ana.22060 CrossRefPubMed

20.

Tolosa E, Hernández B, Linazasoro G, López-Lozano JJ, Mir P, Marey J, Kulisevsky J (2014) Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing early wearing-off: a randomised, double-blind trial. Journal of neural transmission (vienna, austria : 1996) 121(4):357–366. https://doi.org/10.1007/s00702-013-1114-x CrossRef

21.

Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A (2005) Treatment of end-of-dose wearing-off in parkinson’s disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 53(4):197–202. https://doi.org/10.1159/000086479 CrossRefPubMed

22.

Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M (2003) The tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s disease. Eur J Neurol 10(2):137–146CrossRefPubMed

23.

Myllyla VV, Kultalahti ER, Haapaniemi H, Leinonen M (2001) Twelve-month safety of entacapone in patients with Parkinson’s disease. Eur J Neurol 8(1):53–60CrossRefPubMed

24.

Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002) Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105(4):245–255CrossRefPubMed

25.

Kuoppamaki M, Vahteristo M, Ellmen J, Kieburtz K (2014) Pooled analysis of phase III with entacapone in Parkinson’s disease. Acta Neurol Scand 130(4):239–247. https://doi.org/10.1111/ane.12278 CrossRefPubMed

26.

Yi ZM, Qiu TT, Zhang Y, Liu N, Zhai SD (2018) Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation. Ther Clin Risk Manag 14:709–719. https://doi.org/10.2147/tcrm.S163190 CrossRefPubMedPubMedCentral

27.

Rosendaal FR, Reitsma PH (2014) Meta-analysis. J Thromb Haemost 12(7):1009. https://doi.org/10.1111/jth.12616 CrossRefPubMed

28.

Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J et al (2011) The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis—a simulation study. PLoS One 6(10):e25491. https://doi.org/10.1371/journal.pone.0025491 CrossRefPubMedPubMedCentral

Titel: Levodopa/carbidopa/entacapone for the treatment of early Parkinson’s disease: a meta-analysis
verfasst von: Xiaoli Liao
Nianyue Wu
Dongfeng Liu
Bowei Shuai
Shilei Li
Ke Li
Publikationsdatum: 11.03.2020
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 8/2020
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04303-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Levodopa/carbidopa/entacapone for the treatment of early Parkinson’s disease: a meta-analysis

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

Interaktionen zwischen Epilepsie- und COVID-19-Medikamenten

Isolated hemorrhagic arterialized DVAs: revisiting symptomatic DVAs

Type B diencephalic–mesencephalic junction dysplasia, a congenital brainstem malformation that may be silent until adulthood: a case report

Informing MS patients on treatment options: a consensus on the process of consent taking

Sexual dysfunction in male patients with Parkinson’s disease: related factors and impact on quality of life

Platelet dysfunction and coagulation assessment in patients of tuberculous meningitis

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie